Mr. Michael Schmertzler has been the the Chairman of the company's since 2004. Mr. Schmertzler served as a Managing Director of Aries Advisors LLC; the sub-advisor to Credit Suisse First Boston Equity Partners LP; and the Chair of the investment committee of Credit Suisse First Boston Equity Partners LP from 2001 to 2015. He served as Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking firm from 1997 to 2001. Prior to 1997, Mr. Schmertzler served in several management roles with Morgan Stanley and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb and Head of International Sales and Trading and Investment Banking at its successor, Lehman Brothers. Prior to this, he also served as a director of PTC Therapeutics' UK subsidiary until February 2016. Mr. Schmertzler has been an Adjunct Professor and Lecturer at Yale University. He also serves on the Board of Lehman Commercial Paper Inc.

Dr. Matthew B. Klein has been the Chief Executive Officer and Director of the company since March 2023. Prior to this he served as a Chief Operating Officer of the company. Prior to this, he served as the Chief Development Officer of the company since April 2020. Dr. Klein previously served as the Chief Executive Officer and Chief Medical Officer of BioElectron Technology Corp. Prior to that he served as the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington.

Mr. Pierre Gravier has been the Chief Financial Officer of the company since July 2023. Previously, he served as a Managing Director in the healthcare group of Perella Weinberg Partners. Prior to that, Mr. Gravier served as a healthcare investment banker at Barclays Capital.

Ms. Christine Utter has been the Head of People Services, Senior Vice President and Chief Accounting Officer of PTC Therapeutics since 2019. She previously served as the company's Assistant Controller from 2010 till 2017 and as Principal Financial Officer till 2019. Prior to that, Ms. Utter served as the Assistant Corporate Controller of Barrier Therapeutics and a Financial Analyst at Engelhard Corp.

Mr. Mark E. Boulding has been the Executive Vice President and Chief Legal Officer of the company since March 2012. Prior to that, he was the Senior Vice President and General Counsel of the company's from 2002 to 2012. Before that Mr. Boulding served as the General Counsel, Executive Vice President, and Secretary at MedicaLogic/Medscape, and as a partner in two firms based out of Washington DC, the US.